Cutia Therapeutics Phase III Trial for Skin Treatments Presented in Annual CDA Meeting
MT Newswires Live2024-11-28
Cutia Therapeutics (HKG:2487) said the Phase III clinical trial in China of CU-40102, a topical finasteride spray, and CU-30101, a localized topical lidocaine and tetracaine cream, was presented through electronic posters at the 19th Annual Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology, according to a Thursday filing with the Hong Kong bourse.
Topical finasteride spray is used for the treatment of androgenetic alopecia, also known as male pattern baldness. CU-30101 is used for localized topical lidocaine and tetracaine cream for surface dermatologic issues, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
